AstraZeneca News | finanzen.ch

Kurse + Charts + Realtime	News + Analysen	Fundamental	Unternehmen	zugeh. Wertpapiere	Aktion
Kurs + Chart	Chart (gross)	News + Adhoc	Bilanz/GuV	Termine	Strukturierte Produkte	Portfolio
Times + Sales	Chartvergleich	Analysen	Schätzungen	Profil		Watchlist
Börsenplätze	Realtime Push	Kursziele	Dividende/GV
Historisch			Analysen

Kurse + Charts + Realtime

News + Analysen

Fundamental

Unternehmen

zugeh. Wertpapiere

Aktion

Kurs + Chart

Chart (gross)

News + Adhoc

Bilanz/GuV

Termine

Strukturierte Produkte

Portfolio

Times + Sales

Chartvergleich

Analysen

Schätzungen

Profil

Watchlist

Börsenplätze

Realtime Push

Kursziele

Dividende/GV

Historisch

Analysen

24.04.14	AstraZeneca Q1 Profit Falls, Maintains FY14 Outlook (RTTNews)
24.04.14	AstraZeneca Q1 Profit Down; Maintains Outlook - Quick Facts (RTTNews)
20.04.14	Pfizer Makes $100 Bln Bid For AstraZeneca: Reports (RTTNews)
19.03.14	AstraZeneca Unveils Nexium Direct-to-Patient Program - Quick Facts (RTTNews)
17.03.14	AstraZeneca Closes Patient Enrollment Four Months Ahead Of Plan In EUCLID Study (RTTNews)
03.03.14	AstraZeneca: FDA Approves Bydureon Pen In Adults With Type 2 Diabetes (RTTNews)
25.02.14	AstraZeneca Says FDA Approves Orphan Drug Myalept - Quick Facts (RTTNews)
12.02.14	FDA Seeks Clinical Trial Data From AstraZeneca On Diabetes Drug Saxagliptin (RTTNews)
06.02.14	AstraZeneca Posts Loss In Q4, Warns Of FY14; Stock Down (RTTNews)
06.02.14	AstraZeneca Slips To Loss In Q4 - Quick Facts (RTTNews)
03.02.14	AstraZeneca Closes Acquisition Of Bristol's Diabetes Alliance Assets In U.S. (RTTNews)
22.01.14	AstraZeneca : Xigduo Gets Approval In EU To Treat Type 2 Diabetes - Quick Facts (RTTNews)
14.01.14	AstraZeneca Sees 2017 Revenues To Be Broadly In Line With 2013 Revenues (RTTNews)
13.01.14	AstraZeneca: FDA Approves Farxiga To Treat Type 2 Diabetes (RTTNews)
27.12.13	AstraZeneca, Shionogi Extend Crestor Licence Agreement - Update (RTTNews)
27.12.13	AstraZeneca, Shionogi Settle Arbitration, Extend Licence Agreement For Crestor (RTTNews)
19.12.13	Bristol-Myers To Sell Diabetes Business To AstraZeneca In $4.1 Bln Deal (RTTNews)
19.12.13	Bristol-Myers To Sell Its Global Diabetes Business - Quick Facts (RTTNews)
19.12.13	WSJ: Bristol-Myers Nears $3 Bln Deal To Sell Stake In Diabetes JV To AstraZeneca (RTTNews)
13.12.13	AstraZeneca's Lesinurad Meets Primary Goal In Late-stage Study In Gout Patients (RTTNews)
13.12.13	AstraZeneca: Lesinurad Meets Primary Goal In Phase III Study In Gout Patients (RTTNews)
13.12.13	FDA Panel Oks AstraZeneca, Bristol-Myers Diabetes Drug Dapagliflozin In 2nd Try (RTTNews)
13.12.13	AstraZeneca, Bristol-Myers Say FDA Panel Backs Diabetes Drug Dapagliflozin (RTTNews)
12.12.13	Study: Arimidex Halves Breast Cancers Occurrence In High-Risk Women (RTTNews)
12.12.13	AstraZeneca, Bristol-Myers: FDA Panel Recommends Metreleptin For Generalized LD (RTTNews)
12.12.13	AstraZeneca, Bristol-Myers Squibb Announce FDA's EMDAC Recommends Metreleptin (RTTNews)
22.11.13	AstraZeneca: Xigduo Gets Positive CHMP Opinion For Treatment Of Type 2 Diabetes (RTTNews)
19.11.13	Nektar: FDA Accepts New Drug Application For Naloxegol - Quick Facts (RTTNews)
19.11.13	Horizon Pharma Agrees To Buy U.S. Rights To Vimovo - Quick Facts (RTTNews)
19.11.13	AstraZeneca: FDA Accepts NDA For Naloxegol - Quick Facts (RTTNews)
14.11.13	AstraZeneca To Begin Two Addl. Global Trials With Brilinta - Quick Facts (RTTNews)
31.10.13	AstraZeneca Q3 Profit Falls Amid Patent Woes, Names Marc Dunoyer CFO (RTTNews)
31.10.13	AstraZeneca Posts Lower Q3 Profit; Names Marc Dunoyer CFO - Quick Facts (RTTNews)
30.10.13	AstraZeneca Advances MedImmune's Benralizumab To Phase III In Severe Asthma (RTTNews)
22.10.13	AstraZeneca Begins Phase III Study For Selumetinib - Quick Facts (RTTNews)
21.10.13	Evotec, AstraZeneca Collaborate In Kidney Disease - Quick Facts (RTTNews)
18.10.13	Financial Results, Quarterly Earnings Schedules, Marketing Authorizations, Completed Acquisitions, and New Drug Applications - Research Report on Johnson & Johnson, AbbVie, GSK, AstraZeneca, and Keryx (PR Newswire)
17.10.13	Technical Study: AstraZeneca PLC, GlaxoSmithKline PLC, Keryx Biopharma Inc., and Raptor Pharma Corp. (PR Newswire)
15.10.13	AstraZeneca's Research Arm Buys Spirogen - Quick Facts (RTTNews)
14.10.13	AstraZeneca Reports New Safety Data For Naloxegol In Patients With OIC (RTTNews)
07.10.13	New Interactive Tools Empower Women to Express Selves, Raise Awareness on October 13 - Metastatic Breast Cancer Awareness Day (PR Newswire)
03.10.13	Amgen, AstraZeneca To Present Key Studies Evaluating Brodaluma - Quick Facts (RTTNews)
01.10.13	Pharmaceutical Companies Announce Trial Results, and Achieve New Contracts, Regulatory Approvals, and Positive Opinion - Research Report on Eli Lilly, Pfizer, Novartis, Sanofi, and AstraZeneca (PR Newswire)
30.09.13	Presentation, Licensing Agreement, Trial Milestone, Positive Opinion, and Trade Name Acceptance - Research Report on Pfizer, Allergan, Novartis, AstraZeneca, and Rockwell Medical (PR Newswire)
30.09.13	AstraZeneca Says Olaparib Marketing Authorisation Application Accepted By EMA (RTTNews)
26.09.13	AstraZeneca, Bristol-Myers Reports Additional Results From SAVOR Trial (RTTNews)
24.09.13	AstraZeneca, Bristol-Myers Reports Results From Phase III Study Of Dapagliflozin (RTTNews)
20.09.13	AstraZeneca's Flu Vaccine Fluenz Tetra Receives Positive Opinion From CHMP (RTTNews)
19.09.13	Technical Scrutiny: GlaxoSmithKline PLC, Keryx Biopharma Inc., AstraZeneca PLC, and Raptor Pharma Corp. (PR Newswire)
19.09.13	Clinical Trial Results, Litigation Outcomes and Marketing Authorizations - Research Report on Pfizer, GlaxoSmithKline, Sanofi, AstraZeneca, and Neurocrine (PR Newswire)

Aktien Top/Flop

SMI
SPI
SLI
SMIM
DAX
ESTOXX
Dow Jones
S&P 500
NASDAQ 100
Nikkei 225

Nestle	74.64	0.30 %	K V
Swiss Life Hldg	698.80	0.20 %	K V
Kuehne+Nagel Int	207.90	0.19 %	K V
CieFinRichemont	137.50	0.11 %	K V
Swisscom	503.00	0.00 %	K V
Logitech Intl	74.68	-0.53 %	K V
Sika	215.40	-0.55 %	K V
Lonza Grp	535.00	-0.56 %	K V
Swiss Re	130.90	-0.57 %	K V
ABB	49.21	-0.67 %	K V

mehr

24.12.24		Optimismus in New York: NASDAQ 100 verbucht zum Ende des Dienstagshandels Zuschläge
24.12.24		Börse New York in Grün: NASDAQ 100 steigt nachmittags
24.12.24		AstraZeneca-Aktie dennoch fester: AstraZeneca und Daiichi Sankyo rudern bei EU-Zulassungsantrag für Lungenkrebsmittel zurück
23.12.24		AstraZeneca-Aktie höher: EU-Zulassung für Tagrisso gegen weitere Lungenkrebsform
18.12.24		Schwacher Handel in New York: NASDAQ 100 am Mittwochnachmittag schwächer
04.12.24		Zuversicht in New York: NASDAQ 100 zum Handelsstart freundlich
03.12.24		Starker Wochentag in New York: NASDAQ 100 steigt zum Handelsende
03.12.24		Starker Wochentag in New York: NASDAQ 100 am Nachmittag mit Kursplus

24.12.24

Optimismus in New York: NASDAQ 100 verbucht zum Ende des Dienstagshandels Zuschläge

24.12.24

Börse New York in Grün: NASDAQ 100 steigt nachmittags

24.12.24

AstraZeneca-Aktie dennoch fester: AstraZeneca und Daiichi Sankyo rudern bei EU-Zulassungsantrag für Lungenkrebsmittel zurück

23.12.24

AstraZeneca-Aktie höher: EU-Zulassung für Tagrisso gegen weitere Lungenkrebsform

18.12.24

Schwacher Handel in New York: NASDAQ 100 am Mittwochnachmittag schwächer

04.12.24

Zuversicht in New York: NASDAQ 100 zum Handelsstart freundlich